**Sophora alopecuroides** L. var. *alopecuroides* alleviates morphine withdrawal syndrome in mice: involvement of alkaloid fraction and matrine

Saeed Kianbakht 1, 2*fataneh Hashem Dabaghian 1

1Research Institute for Islamic and Complementary Medicine, Iran University of Medical Sciences, Tehran, Iran
2Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran

**ARTICLE INFO**

Article type: Original article

Article history:

Received: Nov 1, 2015
Accepted: Apr 28, 2016

Keywords:

Leguminosae
Mice
Opioid withdrawal
Sophora alopecuroides

**ABSTRACT**

Objective(s): Evaluation of the *Sophora alopecuroides* var. *alopecuroides* seed effects on morphine withdrawal syndrome in mice and determination of the alkaloid composition of the seed total extract.

Materials and Methods: The effects of the seed total extract, alkaloid fraction and major compound matrine on the mice morphine withdrawal syndrome were compared to saline and methadone. Mice were made dependent on morphine by morphine sulfate injection 3 times a day for 3 days. The withdrawal jumping and diarrhea were induced by administration of naloxone 2 hr after the 10th injection of morphine sulfate on the day 4. The total extract (100, 200, 300 mg/kg), alkaloid fraction (5, 10, 20 mg/kg), matrine (5, 15, 30 mg/kg) methadone (10 mg/kg) or saline were injected 30 min before naloxone. All drugs were administered by subcutaneous injection. The total extract alkaloid composition was also determined by gas chromatography (GC) and GC-MS analysis.

Results: All doses of the total extract, alkaloid fraction and matrine as well as methadone decreased jumping and diarrhea significantly compared to the saline. The effects of the total extract and alkaloid fraction were not significantly different from methadone. But, there were significant differences between the effects of matrine and methadone. Matrine, cytisine, sophocarpine and sophoramine were the major alkaloids. There was no nicotine in the total extract.

Conclusion: *S. alopecuroides* var. *alopecuroides* suppresses opioid withdrawal with efficacy comparable to methadone. Matrine may be one of the alkaloids responsible for the effect of the plant.

**Introduction**

Opioid dependence or addiction is a prevalent health and socioeconomic problem. There are 2 kinds of pharmacotherapies for opioid dependence: detoxification and opioid maintenance treatment (OMT). The purpose of detoxification is to provide a safe and comfortable withdrawal from drug. OMT aims to induce avoidance of illicit drug use. Many drugs are used for detoxification including tapered methadone, tapered methadone plus adjunctive medication, other opioid agonists, clonidine, lofexidine, other adrenergic agonists, buprenorphine, and symptomatic medications. Methadone is the most effective drug used in detoxification. Any opioid drug can be used in OMT which is also termed opioid replacement therapy or agonist substitution. Methadone, buprenorphine and injectable diamorphine (heroin) are the drugs usually used in OMT. Methadone maintenance is the gold standard of treatment. New and evolving therapies are compared to this standard (1-3). The current pharmacotherapies of opioid dependence have unfavorable efficacy and safety profile. A substantial number of patients do not respond adequately to the pharmacotherapies. Thus, novel more effective and safer pharmacological treatments for opioid dependence are needed (4-6).

Plants and their bioactive compounds are suitable sources for development of new opioid dependence pharmacotherapies (7, 8). *Sophora alopecuroides* L. var. *alopecuroides* (*S. alopecuroides*) (Leguminosae) is a plant widely distributed in Western and Central Asia. It is up to 1 meter tall perennial herb with rhizome. It has legumes 5-7 cm long, 7-8 mm diameter and cylindrical with spherical seeds (9). The plant seed is administered orally in the Iranian traditional medicine for the treatment of opium, heroin, methamphetamine and...
nicotine addiction, diarrhea and pain. Specifically, the Iranian therapists use the plant for the control of opioid withdrawal syndrome and OMT. The plant demonstrates good human safety profile (no adverse effects) in the usual oral doses (up to 5 g per day of the seed dried aqueous extract). Quinolizidine alkaloids are the main bioactive compounds of S. alopecuroides. More than 20 kinds of alkaloids have been isolated from the plant including matrine, oxymatrin, sophocarpine, oxysophocarpine, cytisine, sophoramine, sophoridine, nicotine and others. The alkaloids have shown anticancer, antimicrobial, immunological, nervous system, cardiovascular and gastrointestinal effects in the pharmacological studies (10, 11). Varenicline is an analogue of cytisine. Cytisine and varenicline are both effective aids to smoking cessation (12). The major alkaloid of S. alopecuroides matrine has a variety of biological activities including analgesic, anti-inflammatory, anti-arrhythmic, anti-tumor, anti-diarrhoea, antiobesity and immunomodulatory effects (13-15). Matrine has been widely used in China for the treatment of cancer, hepatic, cardiac and skin diseases (16). Of note, the phytochemistry of the Iranian S. alopecuroides has not been examined so far. The only study relative to the biological effects of the Iranian S. alopecuroides has demonstrated that it has analgesic effect in the rat formalin test (17). Moreover, there has been no study concerning the effects of S. alopecuroides on drug dependence.

Considering the above data, in the present study, the effects of a standardized extract of the Iranian S. alopecuroides, its alkaloid fraction and major compound matrine on the mice morphine withdrawal syndrome were evaluated and compared with saline and methadone.

**Materials and Methods**

**Plant materials**

The seeds of S. alopecuroides L. var. alopecuroides (Leguminosae) were collected at fruiting stage from Raviz, 60 km Northwest of Rafsanjan, province of Kerman, Iran. The voucher specimen (number 27235) was deposited in the Tehran University Central Herbarium.

**Total extract**

The seeds of plant were dried, powdered (500 g) and macerated with a 90% ethanol solution for 3 days with three changes of the solution. The resulting extract was filtered and evaporated under vacuum into a dried powder extract (30 g, 6%).

**Extraction of alkaloids**

Alkaloid extraction was carried out as described by Kamada et al (1986) (18): 200 ml of CHCl₃· Me OH-NH₄OH (15: 5: 1) was added to 600 mg of total extract, sonicated for 10 min. After filtration, the residue was washed twice with 200 ml of solution. The pooled filtrate was evaporated to dryness. To the residue, 5 ml of CHCl₃ and 2 ml of 1 N H₂SO₄ were added and then the solution was mixed. The CHCl₃ phase was removed and the H₂SO₄ phase was adjusted to pH 10 with 28% NH₄OH. From the solution, alkaloids were extracted once with 2 ml and twice with 1 ml of CHCl₃. The combined extracts were filtered after adding anhydrous Na₂SO₄. The combined filtrates were evaporated to dryness at 40 °C (265 mg).

**GC (gas chromatography) and GC-MS (gas chromatography-mass spectrometry) analysis**

The extraction of alkaloids was analyzed on a Younglin Acm 600 instrument with an FID detector operated with a split/splitless injector (Younglin, Korea) and DB-5 capillary column, 30 m × 0.25 mm i.d., 0.25 μm film thicknesses (Agilent, USA).

Carrier gas: He, linear velocity (u): 30 cm/sec, flow: 0.8 ml/min Injection temperature: 290 °C Injection volume: 1.0 μl Injection mode: Split (1:50).

Temperature program: 50 °C for min, rising at 3 °C /min to 240 °C, then rising at 15 °C/min to 300 °C, held at 300 °C for 3 min. FID (290 °C): H₂ flow: 50 ml/min; air flow: 400 ml/min.

GC/MS analysis was performed on an Agilent 6890/5973 N instrument and DB-5 capillary column (30 m × 0.25 mm i.d., 0.25 μm film thickness). Carrier gas: He, Linear velocity (u): 32.4 cm/sec, flow: 0.8 ml/min. Injection temperature: 290 °C. Injection volume: 1.0 μl Injection mode: split (1:10).

Temperature program: 50 °C, for 5 min, rising at 3 °C/min to 240 °C, then rising at 15 °C/min to 300 °C, held at 300 °C for 3 min. MS interface temperature: 290 °C, MS mode: EI, Ionization voltage: 70 eV; mass range: 40-500 u; scan speed: 3.18 scans/sec interval: 0.50 sec (2 Hz). Data handling was conducted using a Chem. Station (Agilent).

**Identification of the components**

The compounds of the extraction of alkaloids were identified by comparison of their retention indices, which were calculated by using the retention times of injected n-alkanes (C₈-C₂₈) (obtained from Fluka) with the same chromatographic conditions, along with the fragmentation patterns of the mass spectra with those reported in the literatures and the published mass spectra or WILEY library (19-22). The percentage of the identified compounds was calculated based on GC peak areas without any correction factors.

**Drugs**

Morphine sulfate and methadone hydrochloride were purchased from the Darou Paksh Pharmaceutical Company (Tehran, Iran). Naloxone hydrochloride and matrine were obtained from the Sigma-Aldrich and Ningxia Zijinghua companies respectively. For dilution, all drugs and extracts were dissolved in normal saline. The drugs and extracts were
prepared immediately before use and injected subcutaneously in a volume of 5 ml/kg. The doses of total extract, alkaloid fraction, matrine and methadone were as follows. Total extract: 100, 200 and 300 mg/kg; alkaloid fraction: 5, 10 and 20 mg/kg; matrine: 5, 15 and 30 mg/kg; methadone: 10 mg/kg.

**Animals**

Male albino mice weighing between 25-30 g respectively from our own breeding colony were used. The mice were maintained at a temperature of 22-25 °C on a 12 hr dark-light cycle. The animals had access to standard rodent feed and water *ad libitum*. The number of animals used for each dose of the extracts or drugs was 10. All animals were used only once.

**Animal study**

The effects on opioid withdrawal were evaluated using a method described previously (23). To induce morphine dependence in the mice, morphine was given with the following dosage schedule. Morphine was injected thrice a day at 9:30, 13:30 and 17:30 hr using the doses 50, 50 and 75 mg/kg respectively for 3 days. The higher afternoon dose was aimed to minimize overnight withdrawal. Moreover, a 50 mg/kg dose of morphine was given in the 4th day morning (2 hrs before naloxone injection). Hyperactivity and Straub tail effect were noted after morphine injection. Weight loss of 10% without any animal death was also observed.

Naloxone (2 mg/kg) was given 2 hrs after the last injection of morphine in the 4th day. Subsequently, the animals were placed singly on a piece of blotting paper in a cylindrical glass (25 cm in diameter, 40 cm height) for 30 min. Naloxone immediately caused morphine withdrawal signs as jumping and diarrhea. The number of jumps and feces weight during the 30 min period was recorded for each animal. The total extract, alkaloid fraction and matrine as active treatments, methadone (positive control) or saline (negative control) were injected 30 min before naloxone. This study was conducted according to the European Community Guidelines (EEC Directive of 1986; 86/609/EEC) for laboratory animal use and care.

**Statistical analysis**

The animal study results were presented as mean ± standard error of the mean (SEM). One way analysis of variance (ANOVA) followed by Tukey post hoc test was used for data analysis. Significance level was set at 0.05.

**Results**

**GC and GC-MS analysis**

Alkaloid extraction was analysed by capillary GC and GC-MS and the main compounds were determined via areas under the peaks. Matrine (23.2%), cytisine (20.9%), sophoridine (17.2%), n-methyl cytisine (13.4%), sophocarpine (9.1%) and sophoramine (1.2%), were identified as the main components in the alkaloid extract (Table 1). There was no nicotine in the alkaloid extract.

**Animal study**

All doses of the total extract, alkaloid fraction and matrine as well as methadone decreased jumping and diarrhea significantly compared to the saline (Figures 1-6). The effects of the total extract and alkaloid fraction were not significantly different from methadone. But, there were significant differences between the effects of matrine and methadone.

**Table 1.** The major compounds (in terms of percentage of the total alkaloid content) identified in the alkaloid extraction of *Sophora alopecuroides* var. *alopecuroides*

| No. | Compounds | R<sub>c</sub> | K<sub>c</sub> | Percentage of the total alkaloid content |
|-----|-----------|---------------|---------------|----------------------------------------|
| 1   | n-methyl cytisine | 55.3         | 1965          | 13.4                                   |
| 2   | cytisine | 56.1         | 1994          | 20.9                                   |
| 3   | sophocarpine | 64.5         | 2235          | 9.1                                    |
| 4   | sophoridine | 65.1         | 2246          | 17.2                                   |
| 5   | matrine | 66.2         | 2266          | 23.2                                   |
| 6   | sophoramine | 69.8         | 2451          | 1.2                                    |

* Compounds listed in order of elution from the HP-5 MS column;  
* Retention times (as min);  
Kovats indices on a DB-5 column in reference to n-alkanes

![Figure 1. Effects of saline (Sal), methadone (Met) (10 mg/kg, SC), *Sophora alopecuroides* var. *alopecuroides* total extract (TE) (100 mg/kg, 200 mg/kg, 300 mg/kg, SC) on jumping induced by naloxone (2 mg/kg, SC) in groups of 10 morphine dependent mice. Data are given as mean±SEM. P-value<0.001 for all groups compared to the saline. The asterisked columns are significantly different from the saline](image-url)
Kianbakht and Hashem Dabaghian

**Discussion**

The present study is the first study evaluating the alkaloid composition of the Iranian *S. alopecuroides* seeds. The results indicate that matrine, cytisine, sophoridine, n-methyl cytisine, sophocarpine and sophoramine are the major constituents of the Iranian *S. alopecuroides* seeds. The Iranian *S. alopecuroides* has no nicotine. This is in contrast to the Chinese *S. alopecuroides* which contains nicotine (24). Also, the *S. alopecuroides* total extract and alkaloid fraction profoundly reduce the signs of morphine withdrawal. The inhibitory effect of the plant total extract and alkaloid fraction on the opioid withdrawal syndrome is comparable to methadone. Matrine alleviates the morphine withdrawal syndrome markedly less than the total extract and alkaloid fraction. The significant difference between the effects of matrine and methadone shows that the effect of the plant cannot be...
Several studies have reported the involvement of medicinal and aromatic plants from numerous families in opioid detoxification and relapse prevention, particularly non-opioid medications. The results explain the traditional use of the plant in treating opioid dependence in Iran. The efficacy and safety of the plant in opioid detoxification and relapse prevention, particularly non-opioid medications. Also, the effectiveness of the plant in treating opioid dependence in Iran. The plant may be of significance given the paucity of medications approved for opioid addiction: safe and effective alternatives to conventional pharmacotherapy? CNS Drugs 2011; 25:999-1007.

The study was funded by the Research Institute for Islamic and Complementary Medicine affiliated with the Iran University of Medical Sciences (Tehran, Iran).

Acknowledgement

This study was funded by the Research Institute for Islamic and Complementary Medicine affiliated with the Iran University of Medical Sciences (Tehran, Iran).

References

1. Klein JW. Pharmacotherapy for substance use disorders. Med Clin North Am 2016; 100: 891-910.
2. Bell J. Pharmacological maintenance treatments of opioid addiction. Br J Clin Pharmacol 2014; 77:253-263.
3. Diaper AM, Law FD, Melichar JK. Pharmacological strategies for detoxification. Br J Clin Pharmacol 2014; 77:302-314.
4. Reed K, Day E, Keen J, Strang J. Pharmacological treatments for drug misuse and dependence. Expert Opin Pharmacother 2015; 16:325-333.
5. Bailey CP, Husband SM. Novel approaches for the treatment of psychostimulant and opioid abuse - focus on opioid receptor-based therapies. Expert Opin Drug Discov 2014; 9:1333-1344.
6. Tschenkte TM. Where do we stand in the field of anti-abuse drug discovery? Expert Opin Drug Discov 2014; 9:1255-1258.
7. Ward J, Rosenbaum C, Herron C, McCurdy CR, Boyer EW. Herbal medicines for the management of opioid addiction: safe and effective alternatives to conventional pharmacotherapy? CNS Drugs 2011; 25:999-1007.
8. Tabatabai SM, Dashi S, Doosti F, Hosseinzadeh H. Phytotherapy of opioid dependence and withdrawal syndrome: a review. Phytother Res 2014; 28:811-830.
9. Mozaffarian V. Identification of medicinal and aromatic plants of Iran. Farhang Moaser. Iran 2013, p: 850.
10. Lu X, Lin B, Tang JG, Cao Z, Hu Y. Study on the inhibitory effect of total alkaloids of Sophora alopecuroides on osteosarcoma cell growth. Afr J Tradit Complement Altern Med 2014; 11:172-175.
11. Chang A, Cai Z, Wang Z, Sun S. Extraction and isolation of alkaloids of Sophora alopecuroides and their anti-tumor effects in H22 tumor-bearing mice. Afr J Tradit Complement Altern Med 2014; 11:245-248.
12. Leaviss J, Sullivan W, Ren S, Everson-Hock E, Stevenson M, Stevens JW, et al. What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation. Health Technol Assess 2014; 18:1-120.
13. Cheng H, Xia B, Zhang L, Zhou F, Zhang YX, Ye M et al. Matrine improves 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice. Pharmacol Res 2006; 53:202-208.
14. Qiu S, Sun H, Zhang AH, Xu HY, Yan GL, Han Y et al. Natural alkaloids: basic aspects, biological roles, and future perspectives. Chin J Nat Med 2014; 12:401-406.
15. Zhang WL, Zhu L, Jiang JG. Active ingredients from natural botanicals in the treatment of obesity. Obes Rev 2014; 15:957-967.
16. Zhang XL, Xu HR, Chen WL, Chu NN, Li XN, Liu GY et al. Matrine determination and pharmacokinetics in.

Conclusion

*S. alopecuroides* controls morphine withdrawal syndrome to a degree comparable to methadone. Matrine may be one of the alkaloids involved in the effect of *S. alopecuroides*.
human plasma using LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877:3253-3256.

17. Kianbakht S, Hajiaghaee R. Effects of *Sophora alopecuroides* L., *Zingiber officinale* Rosc. and *Melissa officinalis* L. in formalin and straub tail tests. J Med Plants 2014; 13:33-40.

18. Kamada H, Okamura N, Satake M, Harada H, Shimomura K. Alkaloid production by hairy root cultures in *Atropa belladonna*. Plant Cell Rep 1986; 5:239-242.

19. Adams RP. Identification of Essential Oil Components by Gas Chromatography/Quadrupole Mass Spectrometry. 4th ed. Allured Publishing Corporation. USA 2007, pp: 1-8.

20. Wu YJ, Chen JJ, Cheng YY. Determination of sophocarpine, matrine, and sophoridine in KUHUANG injection by GC-MS. J Anal Chem 2005; 60:967-973.

21. Kite GC, Pennington RT. Quinolizidine alkaloid status of *Styphnolobium* and *Cladrastis* (Leguminosae). Biochem Syst Ecol 2003; 31:1409-1416.

22. Lee ST, Cook D, Molyneux RJ, Marcolongo-Pereira C, Stonecipher CA, Gardner DR. The alkaloid profiles of *Sophora nuttalliana* and *Sophora stenophylla*. Biochem Syst Ecol 2013; 48: 58-64.

23. Zarrindast MR, Mohajeri S. Influence of ATP-dependent K+ channels on nicotine-induced inhibition of withdrawal in morphine-dependent mice. Eur J Pharmacol 2006; 552:90-98.

24. Zhang L, Li G, Houghton PJ, Jackson S, Twentyman PR. Alkaloids in *Sophora alopecuroides* seed and relevant tests for activity. Zhongguo Zhong Yao Za Zhi 1997; 22:740-743.

25. Schmeller T, Sauerwein M, Sporer F, Wink M, Muller WE. Binding of quinolizidine alkaloids to nicotinic and muscarinic acetylcholine receptors. J Nat Prod 1994; 57:1316-1319.

26. Boido CC, Tasso B, Boido V, Sparatore F. Cytisine derivatives as ligands for neuronal nicotine receptors and with various pharmacological activities. Farmaco 2003; 58:265-277.

27. Rahman S, Engleman EA, Bell RL. Nicotinic receptor modulation to treat alcohol and drug dependence. Front Neurosci 2015; 8:426.

28. Zarrindast MR, Farzin D. Nicotine attenuates naloxone-induced jumping behaviour in morphine-dependent mice. Eur J Pharmacol 1996; 298:1-6.

29. Kamei J, Xiao P, Ohsawa M, Kubo H, Higashiyama K, Takahashi H et al. Antinociceptive effects of (+)-matrine in mice. Eur J Pharmacol 1997; 337:223-226.

30. Xiao P, Kubo H, Ohsawa M, Higashiyama K, Nagase H, Yan YN, et al. kappa-Opioid receptor-mediated antinociceptive effects of stereoisomers and derivatives of (+)-matrine in mice. Planta Med 1999; 65:230-233.

31. Higashiyama K, Takeuchi Y, Yamauchi T, Imai S, Kamei J, Yajima Y, et al. Implication of the descending dynorphnergic neuron projecting to the spinal cord in the (+)-matrine- and (+)-allomatrine-induced antinociceptive effects. Biol Pharm Bull 2005; 28:845-848.

32. Yin LL, Zhu XZ. The involvement of central cholinergic system in (+)-matrine-induced antinociception in mice. Pharmacol Biochem Behav 2005; 80:419-425.